Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 218

Related Citations for PubMed (Select 19864082)

1.

Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group.

Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, McMahon E, Kantoff PW, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1046-52. doi: 10.1016/j.ijrobp.2009.06.038. Epub 2009 Oct 26.

PMID:
19864082
2.

Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death.

D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):10-5. doi: 10.1016/j.ijrobp.2008.10.082. Epub 2009 Apr 22.

PMID:
19395184
3.

Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations.

Nguyen PL, Chen MH, Renshaw AA, Loffredo M, Kantoff PW, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):337-41. doi: 10.1016/j.ijrobp.2009.01.045. Epub 2009 Apr 22.

PMID:
19395186
4.

Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1439-44. doi: 10.1016/j.ijrobp.2009.03.034. Epub 2009 Jun 18.

PMID:
19540066
5.

Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.

D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW.

Cancer. 2008 Dec 15;113(12):3290-7. doi: 10.1002/cncr.23970.

6.

Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.

D'Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW.

J Clin Oncol. 2008 Jun 20;26(18):2979-83. doi: 10.1200/JCO.2007.15.9699.

9.

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.

Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):15-23.

PMID:
15337535
10.

Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.

Wo JY, Chen MH, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.

J Clin Oncol. 2009 Dec 10;27(35):6000-5. doi: 10.1200/JCO.2009.23.6067. Epub 2009 Oct 26.

11.

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW.

JAMA. 2008 Jan 23;299(3):289-95. doi: 10.1001/jama.299.3.289.

PMID:
18212313
12.

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.

Urology. 2008 Jan;71(1):136-40. doi: 10.1016/j.urology.2007.08.028.

PMID:
18242382
13.

Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.

Kupelian PA, Buchsbaum JC, Patel C, Elshaikh M, Reddy CA, Zippe C, Klein EA.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):704-11.

PMID:
11849793
14.

Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?

Nguyen KH, Horwitz EM, Hanlon AL, Uzzo RG, Pollack A.

Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):377-83.

PMID:
12957248
16.
17.
18.

Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.

Anderson PR, Hanlon AL, Movsas B, Hanks GE.

Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):1025-30.

PMID:
9392540
19.

Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence.

Nguyen PL, Chen MH, Beard CJ, Suh WW, Choueiri TK, Efstathiou JA, Hoffman KE, Loffredo M, Kantoff PW, D'Amico AV.

Cancer. 2010 Feb 1;116(3):610-5. doi: 10.1002/cncr.24818.

20.

High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.

Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J.

Prostate Cancer Prostatic Dis. 2006;9(3):245-53. Epub 2006 Jun 20.

PMID:
16786040
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk